BNGO

Bionano Genomics Inc. (BNGO) | Rumor.io

Bionano Genomics

BNGO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,153

Bullish sentiment (50-day avg)94%

Price to earnings ratio0.03

Market capitalization19.8M

Earnings per share-3.01

Dividend yield (TTM)—

Revenue (annual)28.5M

Net income (annual)-26.4M

Social

What share of all stock conversation is about BNGO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 17

Bionano Genomics, Inc. ($BNGO) has seen significant price movement, up 52% since Monday, following a presentation at the H.C. Wainwright conference where FY2026 revenue was guided at $31-33 million and FY2027 at $50-54 million.
The company's growth path is highlighted as "staggering" by investors, with a potential 62% growth rate in 2027.
$BNGO has experienced increased trading volume and interest, with some investors speculating about a potential short squeeze and the stock's ability to reach higher prices.

Generated by AI

Sentiment

Of the messages about BNGO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	93.08% -6.92	82.66% +27.47
Bearish	—	—	6.92% new	17.34% -27.47

Bullish· Sep 15

$BNGO has a low float of 10M shares, which can lead to explosive volume and momentum trading.
The company has achieved significant milestones, including proposed MolDX Medicare LCD, NY DOH OGM approval, and established CPT codes for reimbursement, which are expected to drive revenue growth.
$BNGO's OGM platform has received independent peer review and affirmation, making it superior to FISH, and the company is expected to commercialize genome analysis, with forward guidance of 50%+ growth by 2027.

Bearish· Mar 23

Bionano Genomics, Inc. (BNGO) has experienced revenue declines in Q4 and full-year 2025, alongside decreased flowcell sales.
The company has a significant reduction in cash and cash equivalents, reflecting ongoing financial pressures, with only $2.9m remaining.
BNGO's weak financial position and potential need for further cash raises, may lead to a decline in its stock price.

Generated by AI

Topics

Of the messages about BNGO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	68.75%	55.2%
Technical Analysis	—	0%	27.08%	21.66%
Analysts	—	0%	2.08%	1.32%
Earnings	—	0%	0%	7.38%
Controversies	—	0%	2.08%	0.54%
Macro	—	0%	0%	13.9%

Earnings· Mar 9

Bionano Genomics reported Q4 2022 revenue of $8.2 million, a 30% increase over Q4 2021, and full-year 2022 revenue of $27.8 million, a 55% increase over 2021.
The company also reported reaching an installed base of 240 Saphyr systems as of year-end 2022, a 46% increase over year-end 2021.
Bionano Genomics provided revenue guidance for 2023, estimating $35.00 million to $38.00 million.

Analysts· Jun 27

Analysts have set a price target of $8.72 for BNGO, citing three potential catalysts.
BNGO's buy consensus is at 100% among 4 analysts, indicating high confidence in the stock.
Analysts emphasize the importance of understanding the "risks" section and contingencies in evaluating BNGO's potential.

Announcements· Mar 23

Bionano Genomics ($BNGO) reported Q4 2025 revenue of $7.95M, a 3% decline YoY, but with improving cost discipline and a 22% drop in operating expenses.
The company guided FY26 revenue to $30M-$33M, driven by continued growth in optical genome mapping (OGM) and software tool utilization.
Bionano's 2026 Clinical Lab Fee Schedule payment determination for OGM use in hematologic malignancies increased by 47%, fortifying the company's position in structural variant analysis.

Macro· Jan 14

Bionano Genomics' Saphyr system enables researchers to detect structural variations in DNA, potentially leading to new diagnostics and therapeutic targets.
The company's platform streamlines the study of chromosome changes, a field known as cytogenetics, and offers a suite of data analysis tools.
Bionano Genomics' focus on ultra-sensitive and ultra-specific structural variation detection positions the company at the forefront of genome analysis technology.

Technical Analysis· Aug 11

$BNGO is trading on support at 3.30-3.40 and may see increased volume at 3-close.
Resistance levels for $BNGO are near $4.34, $4.52, and $4.66, while support is near $3.90, $3.75, and $3.55.
$BNGO's price action may be influenced by the Ichimoku cloud and a potential breakout, with targets at 6.28 and 8.617.

Generated by AI

Community

Of the messages about BNGO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	20%	39.84%	53.77%
Newcomers	—	80%	60.16%	46.23%

Regulars· Sep 15

The stock has seen a significant increase in volume, with 33 million shares traded today, and the author believes this is due to the company's recent clinical studies and growth roadmap.
The author notes that the company's OGM platform has been validated by three independent peer-reviewed studies, and that Bionano will commercialize genome analysis, leaving academic use behind.
The author is bullish on the stock's future, predicting 50%+ growth by 2027 and noting that complete Medicare approval is imminent, with the company's stock price increasing by 19% from their first alert.

Newcomers· Sep 15

The company's lab tests have shown promising results, with one genome-wide structural test capable of matching or beating the current banding + FISH + microarray stack.
The trade is based on a flawed model that priced the company's kit as dead, whereas in reality, the kit has the potential to be a game-changer in the field of heme codes.
The company has the potential to print FY27 $50-54M and FY29 ~$100M with positive EBITDA, making it an attractive investment opportunity.

Generated by AI

News

Bionano Genomics Stock Surges Tuesday: What's Going On? - Bionano Genomics (NASDAQ:BNGO)

Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.

14d agoBenzinga

Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors (MACs), has issued a proposed Local Coverage Determination (LCD) for Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Vari

19d agoYahoo Finance

Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping

22d agoYahoo Finance

Also Discussed

Investors talking about BNGO also mention

#	Name	Attention
1	Pacific Biosciences of California, Inc. Common StockPACB	0%0
2	Nano Dimension Ltd. Sponsored ADRNNDM	0%+0
3	Check-Cap Ltd.CHEK	0%new
4	Senseonics Holdings, Inc.SENS	0%+0
5	Jaguar Health, Inc.JAGX	0.02%-0.02
6	Foresight Autonomous Holdings Ltd. ADRFRSX	0%+0
7	Gevo Inc.GEVO	0.01%-0.01
8	GHSI - Guardion Health Sciences, Inc.	——
9	Ocugen Inc.OCGN	0.02%-0.01
10	Castor Maritime Inc.CTRM	0%0

Bionano Genomics Inc.

Healthcare
Medical Instruments & Supplies

Bionano Genomics Inc. is a life sciences instrumentation company focused on genome analysis. The company develops and commercializes optical genome mapping solutions, including the Saphyr and Stratys systems, along with consumables, sample-preparation kits, and software used to analyze structural variation and other genomic changes. Its platform is designed for researchers and clinicians working in basic, translational, and clinical research, supporting applications in cytogenetics, rare disease studies, reproductive health, prenatal genetics, and oncology research. Bionano Genomics also offers data analysis tools that help laboratories visualize, interpret, and report genomic findings across multiple platforms. Headquartered in San Diego, California and founded in 2003, Bionano Genomics serves customers in global research and clinical markets with an integrated workflow for genome mapping and interpretation.

Website

Location

9540 Towne Centre Drive

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about BNGO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 17

Bionano Genomics, Inc. ($BNGO) has seen significant price movement, up 52% since Monday, following a presentation at the H.C. Wainwright conference where FY2026 revenue was guided at $31-33 million and FY2027 at $50-54 million.
The company's growth path is highlighted as "staggering" by investors, with a potential 62% growth rate in 2027.
$BNGO has experienced increased trading volume and interest, with some investors speculating about a potential short squeeze and the stock's ability to reach higher prices.

Generated by AI

Sentiment

Of the messages about BNGO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	93.08% -6.92	82.66% +27.47
Bearish	—	—	6.92% new	17.34% -27.47

Bullish· Sep 15

$BNGO has a low float of 10M shares, which can lead to explosive volume and momentum trading.
The company has achieved significant milestones, including proposed MolDX Medicare LCD, NY DOH OGM approval, and established CPT codes for reimbursement, which are expected to drive revenue growth.
$BNGO's OGM platform has received independent peer review and affirmation, making it superior to FISH, and the company is expected to commercialize genome analysis, with forward guidance of 50%+ growth by 2027.

Bearish· Mar 23

Bionano Genomics, Inc. (BNGO) has experienced revenue declines in Q4 and full-year 2025, alongside decreased flowcell sales.
The company has a significant reduction in cash and cash equivalents, reflecting ongoing financial pressures, with only $2.9m remaining.
BNGO's weak financial position and potential need for further cash raises, may lead to a decline in its stock price.

Generated by AI

Topics

Of the messages about BNGO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	68.75%	55.2%
Technical Analysis	—	0%	27.08%	21.66%
Analysts	—	0%	2.08%	1.32%
Earnings	—	0%	0%	7.38%
Controversies	—	0%	2.08%	0.54%
Macro	—	0%	0%	13.9%

Earnings· Mar 9

Bionano Genomics reported Q4 2022 revenue of $8.2 million, a 30% increase over Q4 2021, and full-year 2022 revenue of $27.8 million, a 55% increase over 2021.
The company also reported reaching an installed base of 240 Saphyr systems as of year-end 2022, a 46% increase over year-end 2021.
Bionano Genomics provided revenue guidance for 2023, estimating $35.00 million to $38.00 million.

Analysts· Jun 27

Analysts have set a price target of $8.72 for BNGO, citing three potential catalysts.
BNGO's buy consensus is at 100% among 4 analysts, indicating high confidence in the stock.
Analysts emphasize the importance of understanding the "risks" section and contingencies in evaluating BNGO's potential.

Announcements· Mar 23

Bionano Genomics ($BNGO) reported Q4 2025 revenue of $7.95M, a 3% decline YoY, but with improving cost discipline and a 22% drop in operating expenses.
The company guided FY26 revenue to $30M-$33M, driven by continued growth in optical genome mapping (OGM) and software tool utilization.
Bionano's 2026 Clinical Lab Fee Schedule payment determination for OGM use in hematologic malignancies increased by 47%, fortifying the company's position in structural variant analysis.

Macro· Jan 14

Bionano Genomics' Saphyr system enables researchers to detect structural variations in DNA, potentially leading to new diagnostics and therapeutic targets.
The company's platform streamlines the study of chromosome changes, a field known as cytogenetics, and offers a suite of data analysis tools.
Bionano Genomics' focus on ultra-sensitive and ultra-specific structural variation detection positions the company at the forefront of genome analysis technology.

Technical Analysis· Aug 11

$BNGO is trading on support at 3.30-3.40 and may see increased volume at 3-close.
Resistance levels for $BNGO are near $4.34, $4.52, and $4.66, while support is near $3.90, $3.75, and $3.55.
$BNGO's price action may be influenced by the Ichimoku cloud and a potential breakout, with targets at 6.28 and 8.617.

Generated by AI

Community

Of the messages about BNGO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	20%	39.84%	53.77%
Newcomers	—	80%	60.16%	46.23%

Regulars· Sep 15

The stock has seen a significant increase in volume, with 33 million shares traded today, and the author believes this is due to the company's recent clinical studies and growth roadmap.
The author notes that the company's OGM platform has been validated by three independent peer-reviewed studies, and that Bionano will commercialize genome analysis, leaving academic use behind.
The author is bullish on the stock's future, predicting 50%+ growth by 2027 and noting that complete Medicare approval is imminent, with the company's stock price increasing by 19% from their first alert.

Newcomers· Sep 15

The company's lab tests have shown promising results, with one genome-wide structural test capable of matching or beating the current banding + FISH + microarray stack.
The trade is based on a flawed model that priced the company's kit as dead, whereas in reality, the kit has the potential to be a game-changer in the field of heme codes.
The company has the potential to print FY27 $50-54M and FY29 ~$100M with positive EBITDA, making it an attractive investment opportunity.

Generated by AI

Bionano Genomics

Social

Sep 17

Bullish· Sep 15

Bearish· Mar 23

Earnings· Mar 9

Analysts· Jun 27

Announcements· Mar 23

Macro· Jan 14

Technical Analysis· Aug 11

Regulars· Sep 15

Newcomers· Sep 15

Bionano Genomics Stock Surges Tuesday: What's Going On? - Bionano Genomics (NASDAQ:BNGO)

Bionano Genomics at H.C. Wainwright conference: push for clinical scale

Bionano highlights studies showing OGM utility in blood cancers

MolDX proposes Medicare coverage for Bionano genome mapping test

Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms

Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping

Also Discussed

Bionano Genomics Inc.

Company Information

Location

Bionano Genomics Stock Surges Tuesday: What's Going On? - Bionano Genomics (NASDAQ:BNGO)

Bionano Genomics at H.C. Wainwright conference: push for clinical scale

Bionano highlights studies showing OGM utility in blood cancers

MolDX proposes Medicare coverage for Bionano genome mapping test

Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms

Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping

Also Discussed

Social

Sep 17

Bullish· Sep 15

Bearish· Mar 23

Earnings· Mar 9

Analysts· Jun 27

Announcements· Mar 23

Macro· Jan 14

Technical Analysis· Aug 11

Regulars· Sep 15

Newcomers· Sep 15